185 related articles for article (PubMed ID: 36958727)
1. A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease.
Lee D; Clark ED; Antonsdottir IM; Porsteinsson AP
Expert Opin Pharmacother; 2023 Apr; 24(6):691-703. PubMed ID: 36958727
[TBL] [Abstract][Full Text] [Related]
2. An update on the advancements in the treatment of agitation in Alzheimer's disease.
Porsteinsson AP; Antonsdottir IM
Expert Opin Pharmacother; 2017 Apr; 18(6):611-620. PubMed ID: 28300462
[TBL] [Abstract][Full Text] [Related]
3. Advancements in the treatment of agitation in Alzheimer's disease.
Antonsdottir IM; Smith J; Keltz M; Porsteinsson AP
Expert Opin Pharmacother; 2015; 16(11):1649-56. PubMed ID: 26159445
[TBL] [Abstract][Full Text] [Related]
4. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
[TBL] [Abstract][Full Text] [Related]
5. Risks and benefits of current and novel drugs to treat agitation in Alzheimer's disease.
Herrmann N; Wang HJ; Song BX; Bawa KK; Lanctôt KL
Expert Opin Drug Saf; 2022 Oct; 21(10):1289-1301. PubMed ID: 36252087
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments.
Liu CS; Ruthirakuhan M; Chau SA; Herrmann N; Carvalho AF; Lanctôt KL
Curr Alzheimer Res; 2016; 13(10):1134-44. PubMed ID: 27137221
[TBL] [Abstract][Full Text] [Related]
7. Can antidepressant medication relieve agitation in Alzheimer's disease?
Porsteinsson AP; Smith JS; Keltz MA; Antonsdottir IM
Expert Rev Neurother; 2014 Sep; 14(9):969-71. PubMed ID: 25148535
[TBL] [Abstract][Full Text] [Related]
8. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
Caraci F; Santagati M; Caruso G; Cannavò D; Leggio GM; Salomone S; Drago F
F1000Res; 2020; 9():. PubMed ID: 32695312
[TBL] [Abstract][Full Text] [Related]
9. AXS-05: an investigational treatment for Alzheimer's disease-associated agitation.
Ward K; Citrome L
Expert Opin Investig Drugs; 2022 Aug; 31(8):773-780. PubMed ID: 35763451
[TBL] [Abstract][Full Text] [Related]
10. AVP-786 for the treatment of agitation in dementia of the Alzheimer's type.
Garay RP; Grossberg GT
Expert Opin Investig Drugs; 2017 Jan; 26(1):121-132. PubMed ID: 27936965
[TBL] [Abstract][Full Text] [Related]
11. Agitation and aggression in people with Alzheimer's disease.
Ballard C; Corbett A
Curr Opin Psychiatry; 2013 May; 26(3):252-9. PubMed ID: 23528917
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoids for Agitation in Alzheimer's Disease.
Outen JD; Burhanullah MH; Vandrey R; Amjad H; Harper DG; Patrick RE; May RL; Agronin ME; Forester BP; Rosenberg PB
Am J Geriatr Psychiatry; 2021 Dec; 29(12):1253-1263. PubMed ID: 33573996
[TBL] [Abstract][Full Text] [Related]
13. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.
Kirbach S; Simpson K; Nietert PJ; Mintzer J
Clin Drug Investig; 2008; 28(5):291-303. PubMed ID: 18407715
[TBL] [Abstract][Full Text] [Related]
14. Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease.
Wang HJ; Chinna-Meyyappan A; Feldman OJ; Lanctôt KL
Expert Opin Emerg Drugs; 2024 Jun; ():1-15. PubMed ID: 38822731
[TBL] [Abstract][Full Text] [Related]
15. A Literature Review of Methodologies Used in Randomized Clinical Trials of Agitation in Alzheimer's Disease.
Dubé S; Megerian JT; Malamut R
J Prev Alzheimers Dis; 2018; 5(2):120-133. PubMed ID: 29616705
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.
Ehrhardt S; Porsteinsson AP; Munro CA; Rosenberg PB; Pollock BG; Devanand DP; Mintzer J; Rajji TK; Ismail Z; Schneider LS; Baksh SN; Drye LT; Avramopoulos D; Shade DM; Lyketsos CG;
Alzheimers Dement; 2019 Nov; 15(11):1427-1436. PubMed ID: 31587995
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pipelines for Alzheimer's Disease Psychosis and Agitation.
Oguma T; Jino K
Chem Pharm Bull (Tokyo); 2024; 72(7):610-617. PubMed ID: 38945937
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic treatment patterns in Alzheimer's disease patients with agitation: a cohort study using the UK clinical practice research datalink.
Tran CT; Bøg M; Collings SL; Johnson M; Qizilbash N; Lind S; Baker RA; Jørgensen KT
Curr Med Res Opin; 2022 Mar; 38(3):409-416. PubMed ID: 35068266
[TBL] [Abstract][Full Text] [Related]
19. The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease.
Creese B; Da Silva MV; Johar I; Ballard C
Expert Rev Neurother; 2018 Jun; 18(6):461-467. PubMed ID: 29764230
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.
Liu CS; Chau SA; Ruthirakuhan M; Lanctôt KL; Herrmann N
CNS Drugs; 2015 Aug; 29(8):615-23. PubMed ID: 26271310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
